Regeneron: Antibody cocktail works on variants of COVID-19
Regeneron’s antibody cocktail REGEN-COV works on variants of COVID-19 detected in the United Kingdom and South Africa, the company announced on Wednesday, saying Columbia University also independently confirmed the findings.
“As we expected, the virus continues to mutate, and these data show the continued ability of REGEN-COV to neutralize emerging strains, further validating our multi-antibody cocktail approach to infectious diseases,” Regeneron CEO George Yancopoulos said.
The Biomedical Advanced Research and Development Authority (BARDA), part of the United States Department of Health and Human Services partially funded the antibody cocktail development and manufacturing.
Get involved!
Comments